REGN changes
Pick any two versions below to diff them.
- Price
- $904.35 → $959.41(+6.1%)
- Discount category
- Close to intrinsic value → Pricey
- Recent events
- Oct 30, 2026: Regeneron reported Q3 2026 results. Total revenues rose 36% to $5,116 million. Dupixent global net sales, which Sanofi records, rose 35% to $6.5 billion. U.S. sales of EYLEA HD rose 62% to $699 million, and U.S. sales of EYLEA fell 41% to $400 million. Libtayo global sales rose 51% to $550 million. GAAP EPS was $18.45, and non-GAAP EPS was $20.07. The FDA approved Pasatru for fibrodysplasia ossificans progressiva in August 2026. The board declared a dividend of $0.94 per share. Oct 6, 2026: Regeneron and Sanofi amended their antibody collaboration to add several next-generation, long-acting antibodies. Regeneron received a $1.0 billion up-front payment, which it will recognize as collaboration revenue in Q4 2026. It can receive up to $7.0 billion more in milestones, and the companies share costs and profits equally on the new programs. added: Sep 24, 2026: Regeneron gave its co-founders, CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos, one-time performance share awards that replace their yearly equity awards until 2036. The payout depends on new product filings, approvals and revenues over ten years. The maximum payout needs nearly $30 billion of yearly revenue from new products and a positive shareholder return, and the shares cannot be sold before February 2036. Jul 30, 2026: Regeneron reported Q2 2026 results. Total revenues rose 17% to $4,291 million, and non-GAAP EPS was $14.29, including a negative effect of $0.99 from acquired IPR&D. The Sanofi Development Balance was fully repaid by the end of Q2 2026. The FDA accepted the cemdisiran application in generalized myasthenia gravis under priority review, with a target action date in November 2026. In May 2026, a Phase 3 trial of fianlimab with cemiplimab in melanoma did not reach its primary endpoint.